Pharmaceutical company Luye Pharma Group said on Wednesday that it has submitted its New Drug Application (NDA) for LY03005, a new chemical drug for the treatment of major depressive disorder, with US Food and Drug Administration (FDA).
LY03005 is the company's second drug in the central nervous system (CNS) therapeutic area in the FDA's NDA phase. It is an exclusive CNS product developed under Luye Pharma's New Chemical and Therapeutic Entities (NCE/NTE) R&D platform. The drug is a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI), with one of the active metabolites being a serotonin-norepinephrine reuptake inhibitor (SNRI).
Luye Pharma has received patents covering the chemical compound and crystal form in target markets such as China, the US, Europe, Japan and Korea.
Silo Pharma regains compliance with Nasdaq minimum bid price
Lilly acquires 4E Therapeutics to advance non-opioid chronic pain treatment
Bayer receives FDA approval for AMBELVIST MRI contrast agent
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
Verge Labs and Tenacia Biotechnology collaborate on advancing Tenacia's CNS pipeline
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Solvonis Therapeutics secures second US patent for PTSD compound series
Insilico Medicine and Tenacia expand AI-driven R&D collaboration
TheraCryf advances lead addiction programme to final preclinical stage
Collegium to acquire AZSTARYS from Corium Therapeutics
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
GenomOncology partners with WeTrials to support CNS cancer clinical trials
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial